Foundation Medicine Inc., of Cambridge, Mass., and Clovis Oncology Inc., of Boulder, Colo., said they expanded their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a premarket approval companion diagnostic test, designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly (ADP-ribose) polymerase inhibitor.